FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HARDISON DON M					2. Issuer Name and Ticker or Trading Symbol Cytek Biosciences, Inc. [ CTKB ]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last)	(Fi	rst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/05/2024							Officer below)	(give title	Other below	(specify	
C/O CYTEK BIOSCIENCES, INC. 47215 LAKEVIEW BOULEVARD				4	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person				
(Street)	Street) FREMONT CA 94538				Rule 10b5-1(c) Transaction Indication							Form filed by More than One Reporting Person				
(City) (State) (Zip)				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transaction ate Ionth/Day/	Execution Date,		Code (Inst				5. Amour Securitie Beneficia Owned F	s ally ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
					Code V	Amount	(A) or (D) Price		Transact	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, T rity or Exercise (Month/Day/Year) if any C		Code	ransaction of ode (Instr. Derivative		Expiration Date (Month/Day/Year) U		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Units	(1)	06/05/2024		A		15,706		(2)	(2)	Common Stock	15,706	\$0	15,706	D		
Stock Option (right to buy)	\$5.73	06/05/2024		A		23,076		06/05/2025	06/05/2034	Common Stock	23,076	\$0	23,076	D		

## **Explanation of Responses:**

- 1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- 2. 100% of the shares subject to the RSU Award shall vest on June 5, 2025.

/s/ Valerie Barnett, Attorney-in-06/07/2024

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.